Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis(2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase

Anti-Cancer Drug Design

Volumn 11, Issue 7, 1996, Pages 553-567

  Atwell, Graham J ^a   Boyd, Maruta ^a   Palmer, Brian D ^a   Anderson, Robert F ^a   Pullen, Susan M ^b   Wilson, William R ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antibody directed enzyme prodrug therapy; Nitroaniline mustard; Nitroreductase enzyme; Reduction potential

Indexed keywords

5 [N,N BIS(2 CHLOROETHYL)AMINO] 2 NITROBENZAMIDE DERIVATIVE; ANILINE MUSTARD DERIVATIVE; NITROREDUCTASE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG SYNTHESIS; ELECTRON TRANSPORT; ESCHERICHIA COLI; PRIORITY JOURNAL;

BENZAMIDES; CELL SURVIVAL; ESCHERICHIA COLI; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; NITROREDUCTASES; PRODRUGS;

BRASSICACEAE; ESCHERICHIA COLI;

EID: 0029856403     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. ADAMS, G.E., CLARKE, E.D., FLOCKHART, I.R., JACOBS, R.S., SEHMI, D.S., STRATFORD, I.J., WARDMAN, P., WATTS, M.E., PARRICK, J., WALLACE, R.G. & SMITHEN, C.E. (1979). Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. International Journal of Radiation Biology, 35, 133.
2. ANDERSON, R.F. & PATEL, K.B. (1984). Radical cations of some low-potential viologen compounds. Journal of the Chemical Society, Faraday Transactions I, 80, 2693.
3. ANLEZARK, G.M., MELTON, R.G., SHERWOOD, R.F., COLES, B., FRIEDLOS, F. & KNOX, R.J. (1992). The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). 2. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Biochemical Pharmacology, 44, 2289.
4. ANLEZARK, G.M., MELTON, R.G., SHERWOOD, R.F., KNOX, R.J., FRIEDLOS, F., WILSON, W.R., DENNY, W.A. & PALMER, B.P. (1995). Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochemical Pharmacology, 50, 609.
5. BAGSHAWE, K.D. (1994). Antibody-directed enzyme prodrug therapy. Clinical Pharmacokinetic Concepts, 27, 368.
6. BRITISH PATENT 771, 416. (1957). Trichloromethylhalobenzenes. Chemical Abstracts, 51, 16546g.
7. 6O. Acta Crystallographica, C40, 493.
8. CLIFFE, S., THOMPSON, K.M., PALMER, B.D; VAN ZILJ, P. & WILSON, W.R. (1992). Identification of the major hypoxic metabolites of CB 1954 and its nitrogen mustard analogue, SN 23862, in Chinese hamster cells. Collected Abstracts, Radiation Research Society 40th Annual Meeting, Salt Lake City, UT, p. 60 (abstract P-15-4).
9. HANSCH, C. & LEO, A.J. (1979). Substituent Constants for Correlation Analysis in Chemistry and Biology. Wiley, New York.
10. HARRIS, J.D., GUTIERREZ, A.A., HURST, H.C., SIKORA, L. & LEMOINE, N.R. (1994). Gene therapy for cancer using tumor-specific prodrug activation. Gene Therapy, 1, 170.
11. HAY, M.P., WILSON, W.R. & DENNY, W.A. (1995). A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductase. Bioorganic and Medicinal Chemistry Letters, 5, 2829.
12. HUENNEKENS, F.M. (1994). Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates. Trends in Biotechnology, 12, 234.
13. KHAN, A.H. & ROSS, W.C.J. (1969). Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships. Chemico-Biological Interactions, 1, 27.
14. KNOX, R.J., FRIEDLOS, F., SHERWOOD, R.F., MELTON, R.G. & ANLEZARK, G.M. (1992). The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). 2. A comparison of Escherichia coli nitroreductase and Walker DT diaphorase. Biochemical Pharmacology, 44, 2297.
15. MAUGER, A.B., BURKE, P.J., SOMANI, H.H., FRIEDLOS, F. & KNOX, R.J. (1994). Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. Journal of Medicinal Chemistry, 37, 3452.
16. MAURIN J. & KRYGOWSKI, T.M. (1988). Crystallographic studies and physicochemical properties of π-electron systems. Part XIV. Crystal and molecular structure of N,N-dimethyl-p-nitroaniline. Journal of Molecular Structure, 172, 413.
17. 2. Crystal Structure Communications, 4, 413.
18. PALMER, B.D., VAN ZIJL, P., DENNY, W.A. & WILSON, W.R. (1995). Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862). Journal of Medicinal Chemistry, 38, 1229.
19. PALMER, B.D., WILSON, W.R., ATWELL, G.J., SCHULTZ, D., XU, X.Z. & DENNY, W.A. (1994). Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. Journal of Medicinal Chemistry, 37, 2175.
20. PALMER, B.D., WILSON, W.R., CLIFFE, S. & DENNY, W.A. (1992). Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. Journal of Medicinal Chemistry, 35, 3214.
21. PALMER, B.D., WILSON, W.R. PULLEN, S.M. & DENNY, W.A. (1990). Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N′-bis(2-chloroethyl)anilines. Journal of Medicinal Chemistry, 33, 112.
22. PALMER, B.D., WILSON, W.R., ANDERSON, R.F., BOYD, M. & DENNY, W.A. (1996). Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862). Journal of Medicinal Chemistry 39, 2518.
23. SCHINDHELM, H. (1932). 2-Halo-5-nitrobenzene-1,4-dicarboxylic acids. US Patent 1,832,247. Chemical Abstracts, 26, 855.
24. SIIM, B.G., ATWELL, G.J. & WILSON, W.R. (1994). Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. British Journal of Cancer, 70, 596.
25. SPRINGER, C.J. & NICULESCU-DUVAZ, I. (1995). Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Design, 10, 361.
26. SPRINGER, C.J., ANTONIW, P., BAGSHAWE, K.D., SEARLE, F., BISSET, G.M.F. & JARMAN, M. (1990). Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. Journal of Medicinal Chemistry, 33, 677.
27. STECKHAN, E. & KUWANA, F. (1974). Spectroelectrochemical study of mediators. 1. Bipyridylium salts and their electron transfer rates to cytochrome C. Berichte der Bunsen-Gesellschaft fur physikalische Chemie, 78, 253.
28. WALLACE, P.M. & SENTER, P.D. (1994). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Methods and Findings in Experimental and Clinical Pharmacology, 16, 505.